2-Apr-2026
Globe Newswire (Thu, 12-Mar 4:01 PM ET)
Globe Newswire (Thu, 12-Mar 10:26 AM ET)
Globe Newswire (Thu, 12-Mar 9:00 AM ET)
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
Globe Newswire (Tue, 10-Mar 9:25 AM ET)
Globe Newswire (Mon, 9-Mar 8:30 AM ET)
Globe Newswire (Tue, 24-Feb 9:00 AM ET)
Globe Newswire (Tue, 20-Jan 9:15 AM ET)
Capricor’s $150 Million Offering Poised to Accelerate Cell Therapy Development for Rare Diseases
Market Chameleon (Fri, 5-Dec 2:06 AM ET)
Market Chameleon (Thu, 4-Dec 5:41 AM ET)
Capricor’s HOPE-3 Results Show 54% Slowing of Disease Progression in Duchenne Muscular Dystrophy
Market Chameleon (Wed, 3-Dec 5:28 AM ET)
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Capricor Therapeutics trades on the NASDAQ stock market under the symbol CAPR.
As of April 2, 2026, CAPR stock price climbed to $32.11 with 1,184,925 million shares trading.
CAPR has a beta of 2.36, meaning it tends to be more sensitive to market movements. CAPR has a correlation of 0.04 to the broad based SPY ETF.
CAPR has a market cap of $1.85 billion. This is considered a Small Cap stock.
Last quarter Capricor Therapeutics reported $0 in Revenue and -$.62 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.09.
In the last 3 years, CAPR traded as high as $40.37 and as low as $2.68.
The top ETF exchange traded funds that CAPR belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
CAPR has outperformed the market in the last year with a price return of +229.7% while the SPY ETF gained +17.5%. CAPR has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +13.4% and +3.0%, respectively, while the SPY returned -3.7% and -0.1%, respectively.
CAPR support price is $28.48 and resistance is $31.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CAPR shares will trade within this expected range on the day.
